Swiss dental firm vVardis slides 22% in weak NYSE debut
Shares of Swiss dental startup vVardis fell 22% in their NYSE debut after the company priced its $175 million IPO at $18, below range. Source: Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The Swiss company's stock dropped 22% during its first session on the New York Stock Exchange, Reuters reported. Zug-based vVardis raised $175 million by selling 9.7 million shares at $18 each, a price under its marketed $21 to $24 range. Trading opened at $14.
Founded in 2020 by Swiss dentists Haley and Goly Abivardi, the firm sells its Curodont treatments, which aim to reverse early tooth decay without drills or needles. Goldman Sachs, JPMorgan, William Blair, the UBS investment arm and Deutsche Bank Securities managed the offering.
The listing comes amid pressure on the US IPO market, where an AI-led tech sell-off, doubts over AI rules and data center spending after the Democrats' sweeping midterm win, and Jensen Huang's exit as Nvidia CEO have all weighed on sentiment.
why it matters
A weak debut suggests demand for new listings is thin in nervous markets, and pricing below range often means bankers had to cut the valuation to find buyers. For the broader IPO market, it signals that investors are becoming more cautious about new issuers.
market impact
US IPO market: weak debut adds caution toward new listings and pressures fresh offerings
- US IPO market pressure down — a weak debut and pricing below range reduce demand for new shares
tags
instruments
sources
- Swiss dental startup vVardis shares fall in NYSE debut — Reuters, 13 November 2026 at 17:42 UTC
- Swiss dental startup vVardis shares fall in NYSE debut — Reuters, 13 November 2026 at 17:50 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗